Synonyms: 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; LY 170052; 132539-06-1; BCP04917; EBD23216; NSC_4585; ZINC3873830; Tox21_111556; AC-665; ANW-46937; CO0033; s2493; STK634338; Zyprexa; STL388024; ZINC52957434; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; AKOS000282888; AKOS005566122; Olanzapine 1.0 mg/ml in Acetonitrile; Tox21_111556_1; ACN-029909; AN-6960; BCP9001021; Zyprexa Zydis; CCG-100922; CS-1114; DB00334; MCULE-1620364835; NC00172; NCGC00096077-01; NCGC00096077-04; NCGC00096077-05; NCGC00096077-06; NCGC00389791-02; Olansek; BC206213; BR-57874; CJ-20712; CPD000466345; HY-14541; I960; SAM001246652; SC-16244; SBI-0206786.P001; AB0013948; Zalasta; AB1008596; AJ-112146; LS-152313; RT-003566; ST2417070; TL8000772; CAS_132539-06-1; FT-0612957; O0393; SW220248-1; Zyprexa Intramuscular; A10667; C07322; D00454; J10363; S-4287; AB00639907-06; AB00639907-07; AB00639907_08; AB00639907_09; 539O061; Zyprexa Velotab; A806453; L000455; L005958; I06-0784; J-006186; SR-01000759343-4; SR-01000759343-6; Z1868057799; Olanzapine, European Pharmacopoeia (EP) Reference Standard; Olanzapine, United States Pharmacopeia (USP) Reference Standard; olanzapinum; Olanzapine, Pharmaceutical Secondary Standard; Certified Reference Material; (E)-2-methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine; 2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine #; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-benzo[b]thieno[2,3-e][1,4]diazepine; 5h-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; Olanzapine for system suitability, European Pharmacopoeia (EP) Reference Standard; Olanzapine-d8, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material; LY-170053; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; Lanzac; Zyprexa; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0(3),?]tetradeca-1(14),3(7),5,8,10,12-hexaene; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0(3),]tetradeca-1(14),3(7),5,8,10,12-hexaene; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),2,5,7,11,13-hexaene; Olanzapine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material; Symbyax; Integrol; Olazax; Olanzapine pamoate; Olanzapine Teva; Zolafren; Olazax Disperzi; Mixture Name; Zyprexa Relprevv; Zyprexa (TN); olanzapine embonate; Olanzapine Glenmark; Zolafren (TN); Olzapin (TN); Rexapin (TN); Zalasta (TN); LY 170053; Zypadhera; Zydis (TN); Lilly brand of olanzapine; Olanzapine Glenmark Europe; D0V4QS; Olanzapine pamoate monohydrate; Eli Lilly brand of olanzapine; CID4585; C17-H20-N4-S; CS-O-30992; LY170052; Lanzac; LY 170052; B2240; C076029; D000077152; 10H-tieno [2,3-b] [1,5 benzodiazepina], 2-metil-4-(4-metil-1-piperacinil)-; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 57-88-5; Olanzapine, 99%, a high affinity for 5-HT2 serotonin and D2 dopamine receptor antagonist - 1g 1g; 2-Methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine; LY 170053; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; Olzapin; Oferta; UNII-N7U69T4SZR; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 10H-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; LY-170052; CHEMBL715; N7U69T4SZR; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; CHEBI:7735; C17H20N4S; KVWDHTXUZHCGIO-UHFFFAOYSA-N; MFCD00866702; olanzapina; NCGC00096077-03; LY170052; LY170053; DSSTox_CID_3388; DSSTox_RID_77010; DSSTox_GSID_23388; Midax; Zydis; Olanzapine [USAN:INN]; Olanzapine Mylan; 2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-5H-thieno[3,2-c][1,5]benzodiazepine; olanzapine; Olanzapine Teva; 10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene; Olanzapine (OLA); SMR000466345; Olanzapine Neopharma; CAS-132539-06-1; SR-01000759343; Olanzapin; Olanzapine (JAN/USAN/INN); olanzapine pamoate; LY-170052; ALKS-7921; HSDB 8155; Olanzapine [USAN:USP:INN:BAN]; Olanzapine(Zyprexa); Olanzapine (Zyprexa); KS-1090; AC1L1IHS; ACMC-209wx7; GTPL47; Zolafren; BIDD:PXR0138; SCHEMBL28763; US8802672, Olanzapine; KSC177A9B; MLS000759457; MLS001165781; MLS001195646; MLS001424057; BIDD:GT0332; SCHEMBL117695; Zyprexa; SPECTRUM1505024; Jsp001969; DTXSID9023388; Olanzapine, >=98% (HPLC); BDBM35254; BDBM82479; CHEBI:94534; CTK0H7090; CTK6I2959; KS-00000XJV; olanzapine; HMS2051H05; HMS2089M04; HMS2093I04; HMS2233F24; HMS3374L02; HMS3393H05; HMS3657I15; HMS3714J03; ACT03231; ALBB-027265;